title: Malignant mixed müllerian tumor of the uterine corpus--analysis of 12 cases.
abstract: Clinical and histopathological features of 12 patients with malignant mixed müllerian tumor of the uterine corpus presenting to Chang Gung Memorial Hospital from January 1988 to September 1993 were retrospectively investigated. The age distribution ranged from 43 to 76 years with a median of 56, and post-menopausal bleeding was the most common symptom in these patients. There was 60% (6/10) of discrepancy in histologic diagnosis between the specimens of dilatation and curettage and that of hysterectomy. All patients received total hysterectomy and bilateral salpingo-oophorectomy, and 10 with retroperitoneal lymph node dissection. Nine patients received cisplatin based chemotherapy, one received radiation only, one received sequential chemotherapy and irradiation, and one underwent concurrent chemoradiation as adjuvant. Two-year survival in patients with stage I-II was 70% (95% C.I.: 34%, 100%) and that of stage III, 25% (95% C.I.: 0.67%). There was 42% (5 of 12) progression/recurrence rate, all developed within 2 years. An effective adjuvant chemotherapy after comprehensive surgery including a total abdominal hysterectomy, bilateral salpingo-oophorectomy and lymph node dissection may be needed for a satisfactory improvement in the patients' survival.
authors.affiliation: Department of Obstetrics & Gynecology, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
authors.forename: K G
authors.initials: KG
authors.lastname: Huang
authors.forename: T C
authors.initials: TC
authors.lastname: Chang
authors.forename: C H
authors.initials: CH
authors.lastname: Lai
authors.forename: S
authors.initials: S
authors.lastname: Hsueh
authors.forename: C J
authors.initials: CJ
authors.lastname: Tseng
authors.forename: Y K
authors.initials: YK
authors.lastname: Soong
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D018200:Mixed Tumor, Mullerian / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D014594:Uterine Neoplasms / Q000473:pathology / Q000628:therapy*